Stay updated on Flotetuzumab in PIF/ER AML Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.

Latest updates to the Flotetuzumab in PIF/ER AML Clinical Trial page
- Check5 days agoChange Detected- Revision tag updated from v3.4.2 to v3.4.3 on the page. This appears to be a minor maintenance update and does not affect the study information presented.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; deleted the government funding lapse notice and Revision: v3.4.1, representing administrative site updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedA government-funding notice was added about the NIH Clinical Center's status, and the page revision version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check48 days agoChange DetectedShow glossary is now available; Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0 are added, while Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check84 days agoChange DetectedIntroduced a consolidated Locations section listing states and District of Columbia (California, District of Columbia, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New York, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington, Wisconsin) and removed the separate per-state location pages.SummaryDifference1%

Stay in the know with updates to Flotetuzumab in PIF/ER AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.